ClinicalTrials.gg

Program

Oxaliplatin

Also written as “oxaliplatin”, “Oxaliplatin (SR96669)” and “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”.

Its studies are mostly in Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Rectal Neoplasms · Carcinoma, Hepatocellular, led by 9 companies.

Furthest: phase 4, since Aug 10, 200566 company-led studies, 2 open or runningNext primary completion: Mar 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi360 open or runningphase 4since Aug 10, 2005Jan 6, 2001none ahead
Hoffmann-La Roche201 open or runningphase 4since Dec 18, 2007Sep 15, 2003Mar 22, 2027phase 1 · NCT06624085
Prologue Research International30 open or runningphase 3since Jun 5, 2003May 6, 2001none ahead
Pfizer21 open or runningphase 3since Oct 5, 2020Nov 6, 2007none ahead
criterium-inc10 open or runningphase 2since Sep 24, 2019Sep 24, 2019none ahead
GlaxoSmithKline10 open or runningphase 1since Sep 27, 2007Sep 27, 2007none ahead
nang-kuang-pharmaceutical-co-ltd10 open or runningphase 2since Mar 28, 2011Mar 28, 2011none ahead
NovoCure10 open or runningno phasesince Feb 20, 2020Feb 20, 2020none ahead
sirtex-medical10 open or runningphase 3since Aug 13, 2008Aug 13, 2008none ahead

Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, Ono Pharmaceutical, Merck KGaA, Darmstadt, Germany, Eli Lilly, parexel, Halozyme Therapeutics, biolinerx-ltd, AbbVie, Zai Lab, Amgen, Bristol-Myers Squibb, Regeneron Pharmaceuticals and yakult-honsha-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Sep 15, 2003.

  1. Jul 7, 2010Phase 2 study in Colorectal NeoplasmsHoffmann-La Roche · NCT01159171 · 50 enrolled · Italy
  2. Nov 19, 2010Phase 3 study in Carcinoma, HepatocellularSanofi · NCT01245582
  3. Mar 28, 2011nang-kuang-pharmaceutical-co-ltd's first study: phase 2 study in Head and Neck NeoplasmsNew to nang-kuang-pharmaceutical-co-ltdnang-kuang-pharmaceutical-co-ltd · NCT01370876 · 46 enrolled · Taiwan
  4. Jan 10, 2012Phase 3 study in Stomach NeoplasmsSanofi · NCT01515748 · 530 enrolled · Korea, Republic of
  5. Dec 10, 2012Phase 2 study in Stomach NeoplasmsHoffmann-La Roche · NCT01748773 · 34 enrolled · Turkey
  6. Sep 13, 2013Phase 2 study in Colorectal Cancer MetastaticSanofi · NCT01955629 · 4 enrolled · Italy
  7. May 15, 2014Phase 2 study in Colorectal NeoplasmsHoffmann-La Roche · NCT02141295 · 197 enrolled · United States, Australia, Austria and more
  8. Sep 24, 2015Phase 3 study in Stomach NeoplasmsHoffmann-La Roche · NCT02560974 · 1,035 enrolled · China, Korea, Republic of, Taiwan
  9. Feb 25, 2016Phase 2 study in Rectal NeoplasmsHoffmann-La Roche · NCT02694718 · 60 enrolled · Switzerland
  10. Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
  11. Sep 24, 2019criterium-inc's first study: phase 2 study in Colorectal Cancer MetastaticNew to criterium-inccriterium-inc · NCT04169347 · 27 enrolled · United States
  12. Feb 20, 2020NovoCure's first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
  13. Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
  14. Oct 1, 2024Phase 1 study in LymphomaHoffmann-La Roche · NCT06624085 · 50 enrolled · United States, Puerto Rico

Ahead

  1. Mar 22, 2027Primary completion: phase 1 study in LymphomaHoffmann-La Roche · NCT06624085

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The newest 60 of 66 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06624085Lymphoma · United States, Puerto Rico1Active, not recruitingHoffmann-La RocheMar 22, 202750
NCT04607421Neoplasms · United States, Argentina, Australia and more3Active, not recruitingPfizerMar 1, 2025841
NCT04281576Stomach Neoplasms · Hong Kong–CompletedNovoCureJun 7, 202428
NCT04169347Colorectal Cancer Metastatic · United States2UNKNOWNcriterium-incDec 202427
NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more2TerminatedHoffmann-La RocheOct 9, 2025219
NCT02694718Rectal Neoplasms · Switzerland2CompletedHoffmann-La RocheAug 200660
NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan3CompletedHoffmann-La RocheNov 20121,035
NCT02141295Colorectal Neoplasms · United States, Australia, Austria and more2TerminatedHoffmann-La RocheJul 29, 2016197
NCT01955629Colorectal Cancer Metastatic · Italy2TerminatedSanofiMar 20154
NCT01748773Stomach Neoplasms · Turkey2CompletedHoffmann-La RocheAug 21, 201534
NCT01515748Stomach Neoplasms · Korea, Republic of3CompletedSanofiJan 21, 2019530
NCT01370876Head and Neck Neoplasms · Taiwan2Terminatednang-kuang-pharmaceutical-co-ltdAug 201146
NCT01245582Carcinoma, Hepatocellular3WithdrawnSanofiFeb 20140
NCT01159171Colorectal Neoplasms · Italy2CompletedHoffmann-La RocheJul 201050
NCT01135498Colorectal Neoplasms · Spain2CompletedHoffmann-La RocheApr 201090
NCT01130337Stomach Neoplasms · Spain2CompletedHoffmann-La RocheJun 201436
NCT01121848Pancreatic Neoplasms · Canada3CompletedSanofiOct 2013108
NCT01077739Colorectal Neoplasms · Belgium2CompletedHoffmann-La RocheJan 201275
NCT00988897Colorectal Neoplasms · Canada2WithdrawnSanofiMay 20120
NCT00816543Stomach Neoplasms · Korea, Republic of2CompletedSanofiMay 201241
NCT00782041Uterine Neoplasms · Thailand2TerminatedSanofiAug 200311
NCT00735241Colorectal Neoplasms · United States3Withdrawnsirtex-medicalMar 20090
NCT00700570Colorectal Neoplasms · Taiwan2CompletedHoffmann-La RocheNov 201145
NCT00642603Colorectal Neoplasms · United States2TerminatedHoffmann-La RocheMar 200941
NCT00623805Colorectal Neoplasms · Turkey3CompletedHoffmann-La RocheMay 2012123
NCT00612495Endometrial Neoplasms · France2CompletedSanofi31
NCT00611962Neoplasms, Germ Cell and Embryonal · France2CompletedSanofi27
NCT00611754Head and Neck Neoplasms · France2CompletedSanofi15
NCT00611507Stomach Neoplasms · Colombia2CompletedSanofi21
NCT00577031Colorectal Neoplasms · Italy4CompletedHoffmann-La RocheAug 2011205
NCT00559455Carcinoma, Hepatocellular · Korea, Republic of2CompletedSanofiJan 201038
NCT00555620Stomach Neoplasms · Korea, Republic of1CompletedPfizerAug 201076
NCT00536809Colorectal Neoplasms · United States1CompletedGlaxoSmithKlineOct 31, 200812
NCT00499850Adenocarcinoma · Australia1CompletedSanofiJun 200618
NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more3CompletedSanofiMar 2010371
NCT00439426Nasopharyngeal Neoplasms · Morocco2CompletedHoffmann-La RocheSep 200925
NCT00436800Nasopharyngeal Neoplasms · Hong Kong2CompletedSanofiOct 200841
NCT00436241Stomach Neoplasms · Taiwan2CompletedHoffmann-La RocheNov 201045
NCT00421824Rectal Neoplasms · Spain2CompletedSanofiNov 2010108
NCT00411229Stomach Neoplasms · China, Korea, Republic of, Taiwan3CompletedSanofiNov 20121,035
NCT00403624Rectal Neoplasms2CompletedSanofiNov 200538
NCT00399750Colorectal Neoplasms · United States2CompletedSanofi373
NCT00382720Stomach Neoplasms · United States, Belgium, France and more2CompletedSanofiApr 2010275
NCT00356122Carcinoma, Non-Small-Cell Lung · United States2CompletedSanofiAug 201053
NCT00353262Colorectal Neoplasms · Canada1CompletedHoffmann-La RocheSep 200636
NCT00345761Colorectal Neoplasms · Japan2CompletedHoffmann-La RocheOct 200864
NCT00296816Ovarian Neoplasms · United States2CompletedSanofiAug 2011132
NCT00280618Carcinoma, Hepatocellular2CompletedSanofiNov 2006
NCT00275210Colonic Neoplasms · Australia, Austria, Belgium and more3CompletedSanofiApr 20032,246
NCT00271271Carcinoma, Non-Small-Cell Lung · France2CompletedSanofi40
NCT00263354Stomach Neoplasms2CompletedSanofiJul 200620
NCT00263055Colonic Neoplasms · China, Hong Kong, Korea, Republic of and more4CompletedSanofiJun 2005
NCT00263029Rectal Neoplasms2CompletedSanofiMar 200718
NCT00261092Pancreatic Neoplasms · Korea, Republic of2CompletedSanofi48
NCT00259363Rectal Neoplasms · Spain2TerminatedSanofiJun 200646
NCT00174616Rectal Neoplasms · Belgium, France, Germany and more2CompletedSanofiNov 200787
NCT00174564Biliary Tract Neoplasms2CompletedSanofiSep 200667
NCT00129870Colorectal Neoplasms · United States4TerminatedSanofi180
NCT00094965Gastrointestinal Neoplasms · United States2CompletedSanofiAug 200743
NCT00069121Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedHoffmann-La RocheApr 21, 20111,886

How it is read

Names in the registry

  • “Oxaliplatin”, 51 entries
  • “oxaliplatin”, 20 entries
  • “Oxaliplatin (SR96669)”, 3 entries
  • “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
  • “OXALIPLATIN”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.